Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Oncology Année : 2022

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Maya Gottfried
  • Fonction : Auteur

Dates et versions

hal-04385399 , version 1 (10-01-2024)

Identifiants

Citer

Aurelien Marabelle, Dung T. Le, Paolo A. Ascierto, Anna Maria Di Giacomo, Ana de Jesus-Acosta, et al.. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.. Journal of Clinical Oncology, 2022, Journal of Clinical Oncology, 38, pp.1-10. ⟨10.1200/JCO.19.02105⟩. ⟨hal-04385399⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More